Clinical Trial Update: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs [Phase 1]

View source ↗

Summary

A Phase 1 trial by Cellenkos evaluating a combination of T-regulatory cell therapy for myelofibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• T-regulatory cell therapy

Snippet

Sponsor: Cellenkos, Inc. | Conditions: Myelofibrosis | Phase 1 | Status: RECRUITING